8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 26, 2025

TAO Synergies Inc.

(Exact name of registrant as specified in its charter)

1185

Avenue of the Americas, 3rd Floor New York, New York 10036 (Address of principal executive offices and zip code)

Registrant’s telephone number, including

area code: (973) 242-0005

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company. x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election ofDirectors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignations of Mr. Schechter and Dr. Tuchman

On August 28, 2025, Jonathan Schechter resigned from his position as a member of the board of directors (the “Board”) of TAO Synergies Inc. (the “Company”) and as a member of all committees of the Board on which he serves. Mr. Schechter’s resignation was voluntary and not the result of any disagreement with the operations, policies or practices of the Company.

Additionally, on August 28, 2025, Dr. Alan Tuchman, M.D. resigned from his position as a member of the Board and as a member of all committees of the Board on which he serves. Mr. Tuchman’s resignation was voluntary and not the result of any disagreement with the operations, policies or practices of the Company. Upon his resignation, Mr. Tuchman will continue to serve as the Company’s Chief Medical Officer.

Appointment of Mr. Ephron

In connection with the aforementioned resignations, on August 29, 2025, the Company appointed Robert Ephron to the Board. Mr. Ephron joins the Company from JK Polk Holdings where he has served as an advisor in advertising and sales since 2024. Mr. Ephron was previously vice president of advertising and sales at Paramount from 2017 to 2023 and vice president of advertising and sales at Viacom from 2015 to 2017. Mr. Ephron received his Bachelor of Science from the University of Denver. Mr. Ephron will serve on the audit, compensation and nominating and corporate governance committees of the Board. In connection with his appointment to the Board, Mr. Ephron has waived his entitlement to an initial option grant upon joining the Board pursuant to the Company’s non-employee director compensation policy.

The Company is not aware of any transaction in which Mr. Ephron has an interest that would require disclosure under Item 404(a) of Regulation S-K.

Item 7.01. Regulation FD.

On August 26, 2025, the Company issued a press release announcing it has engaged Joseph Jacks as an advisor to its digital asset treasury strategy led by James Altucher. A copy of the press release is attached as Exhibit 99.1 hereto.

The information in this Item 7.01 to this Current Report on Form 8-K, and in Exhibit 99.1 furnished herewith, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item8.01. Other Events.

In connection with the engagement of Joseph Jacks, the Company entered into a consulting agreement with a term of one year with Mr. Jacks, pursuant to which the Company issued warrants exercisable for 100,000 shares of common stock, at an exercise price of $8.40 per share. The warrants will expire five years from the date of issuance.

Item9.01. Financial Statements and Exhibits.

(d) Exhibits

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit99.1

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

JosephJacks to support Company's TAO pure-play treasury initiatives

TAOtreasury strategy anchored at intersection of decentralized AI and cryptocurrencies

NEW YORK, Aug. 26, 2025 /PRNewswire/ -- TAO Synergies Inc. (Nasdaq: TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (DeAI), today announced that it has engaged Joseph Jacks as an advisor to its digital asset treasury strategy led by James Altucher. Mr. Jacks is widely recognized as the leading innovator, builder and funding partner within the Bittensor ecosystem and steward of its open-source infrastructure and subnet code repositories.

"Joseph is an early pioneer in open-source development—the key force behind decentralized AI," said James Altucher, leader of the Company's digital asset treasury strategy. "His deep expertise and vision for Bittensor have made the network one of the most dynamic and transparent open-source AI projects. In turn, Bittensor's native token, TAO, has emerged as the highest-valued AI cryptocurrency. We are honored to welcome Joe as an advisor for our digital asset treasury strategy."

Joseph Jacks is the co-founder and CEO of blockchain services company Latent Holdings, the leading Bittensor lab responsible for stewarding most of the open-source toolchain and infrastructure key subnet code repositories for Bittensor. Latent also operates subnets #14, TAOHash, and #5, Hone, in the Bittensor ecosystem.

In 2018, Jacks founded OSS Capital, the world's first and only venture capital firm dedicated exclusively to early-stage COSS (commercial open source) startups. With OSS he led a $10.5 million series A funding round for Manifold Labs, the largest VC investment in a Bittensor subnet to date. In total, Mr. Jacks has directed OSS to lead more than 40 rounds of inception/seed stage investments representing over $200 million in funding.

Mr. Jacks added, "I'm excited to collaborate with the first and largest pure-play public TAO treasury company. TAO Synergies' crypto strategy is not just about acquiring and staking tokens to generate yield — it's also about actively contributing to the Bittensor ecosystem in ways that will generate even more TAO revenue beyond simply staking tokens."

AboutTAO SynergiesTAO Synergies Inc. is the first pure-play public company focused on the convergence between cryptocurrency and artificial intelligence. The Company's differentiated cryptocurrency  treasury strategy is centered exclusively on the acquisition of TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and AI. TAO Synergies Inc. seeks to stake TAO for revenue generation and capital appreciation, a strategy that underscores its mission to create significant value for shareholders. Further information is available at taosynergies.com.

Forward-LookingStatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.

Contact800-811-5591

ir@taosynergies.com

SOURCE TAO Synergies Inc.